Development of personalized therapy for patients with CpG island methylator phenotype renal cell carcinoma

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K09727
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: University of Toyama
• Principal Investigator: Hiroshi Kitamura 富山大学, 学術研究部医学系, 教授 (00404674)
• Co-Investigator(Kenkyū-buntansha): 新井 恵吏 慶應義塾大学, 医学部(信濃町), 准教授 (40446547) ; 西山 直隆 富山大学, 学術研究部医学系, 講師 (70619030)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 腎細胞がん / CpGアイランドメチル化形質 / コンパニオン診断

Outline of Final Research Achievements

After obtaining written explanation and consent, surgical specimens were collected from patients scheduled for surgery for renal cell carcinoma and DNA was extracted using a DNA methylation quantification system based on high performance liquid chromatography [HPLC]. CpG island methylator phenotype [CIMP] determination was performed. A total of 383 cases were enrolled and 192 analyses have been completed to date. HPLC and CIMP determination of all cases will be completed in the first half of 2023. The prognostic and pathological characteristics of each case are currently being investigated and the relevance to CIMP determination will be examined in the future.

Free Research Field

泌尿器科学

Academic Significance and Societal Importance of the Research Achievements

多層オミックス統合解析により同時に同定したコンパニオン診断マーカーと治療標的を用いることで、転移・再発を来たしやすい難治がんである腎細胞がん症例を、診断と予後予測システムを確立し得た。またCIMP陽性症例に対する新規治療を樹立するための基盤となる知見を得ることができた。